The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer

Cancer

Volumn 83, Issue 8, 1998, Pages 1471-1482

  Miller Jr , Wilson H ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer; Differentiation; Liarozole; Retinoic acid; Retinoic acid metabolism blocking agents (RAMBAs); Retinoids

Indexed keywords

LIAROZOLE; RETINOIC ACID; RETINOIC ACID METABOLISM BLOCKING AGENT; RETINOID; UNCLASSIFIED DRUG;

CANCER INVASION; CANCER PREVENTION; CANCER THERAPY; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG SAFETY; EYE TOXICITY; HEADACHE; METASTASIS INHIBITION; PRIORITY JOURNAL; PROGNOSIS; RETINOL INTOXICATION; REVIEW; SKIN TOXICITY; TUMOR DIFFERENTIATION;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CHEMOPREVENTION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; NEOPLASMS; PHENOTYPE; RECEPTORS, RETINOIC ACID; RETINOIDS; TRETINOIN;

EID: 15644378537     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981015)83:8<1471::AID-CNCR1>3.0.CO;2-6     Document Type: Review

References (146)

1. Sporn MB. Carcinogenesis and cancer: different perspectives on the same disease. Cancer Res 1991;51:6215-8.
2. Warrell RP Jr. Differentiating agents. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Volume 1. 5th edition. Philadelphia: J.B. Lippincott, 1997:483-90.
3. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35:1332-8.
4. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994;12(4):851-73.
5. Moon RC, Mehta RG, Rao KVN. Retinoids and cancer in experimental animals. In: Sporn MB, Roberts AM, Goodman DS, editors. The retinoids: biology, chemistry and medicine. 2nd edition. New York: Raven Press, 1994:573-95.
6. Lotan R. Retinoids in cancer chemoprevention. FASEB J 1996;10:1031-9.
7. Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 1980;605: 33-91.
8. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer chemotherapy. J Clin Oncol 1992;10(5):839-64.
9. Sporn MB, Roberts AB, DeWitt SG. The retinoids: biology, chemistry and medicine. 2nd edition. New York: Raven Press 1994.
10. Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Ann Oncol 1992;3:513-26.
11. Hill DL, Grubbs CJ. Retinoids and cancer prevention. Annu Rev Nutr 1992;12:161-81.
12. Hong WK, Itri L. Retinoids and human cancer. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids: biology, chemistry and medicine. 2nd edition. New York: Raven Press, 1994:597-630.
13. Blomhoff R, Green MH, Berg T, Norum KR. Transport and storage of vitamin A. Science 1990;250:399-404.
14. Blaner WS, Olson JA. Retinol and retinoic acid metabolism. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids: biology, chemistry and medicine. 2nd edition. New York: Raven Press, 1994:229-55.
15. Tang G, Russell RM. 13-cis-retinoic acid is an endogenous compound in human serum. J Lipid Res 1990;30:175-82.
16. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, et al. 9-cis-retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992;68:397-406.
17. Lupulescu A. The role of vitamins A, E and C in cancer cell biology. Int J Vitam Nutr Res 1993;63:3-14.
18. Chytil F. Retinoic acid: biochemistry and metabolism. J Am Acad Dermatol 1986;15:741-7.
19. Marcus R, Coulston AM. Fat-soluble vitamins: vitamins A, K and E. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 8th edition. New York: Pergamon Press, 1990:1553-71.
20. Bruel AG, Benoit G, De Nay D, Brown S, Lanotte M. Distinct apoptotic responses in maturation sensitive and resistant t(15;17) acute promyelocytic leukemia NB4 cells. 9-cis retinoic acid induces apoptosis independent of maturation and Bcl-2 expression. Leukemia 1995;9:1173-84.
21. Mehta R, Barua AB, Moon RC, Olson JA. Interactions between retinoid β-glucuronides and cellular retinol and retinoic acid-binding proteins. Int J Vitam Nutr Res 1992;62: 143-7.
22. Pasquali D, Thaller C, Eichelle G. Abnormal level of retinoic acid in prostate cancer tissues. J Clin Endocrinol Metab 1996;81:2186-91.
23. Giguere V, Ong ES, Segui P, Evans RM. Identification of a receptor for the morphogen retinoic acid. Nature 1987;330: 624-9.
24. Petkovitch M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987;330:444-50.
25. Krust A, Kastner P, Petkovitch M, Zelent A, Chambon P. A third human retinoic acid receptor, hRAR gamma. Proc Natl Acad Sci USA 1989;86:5310-4.
26. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990;345:224-9.
27. Evans RM. The steroid and thyroid hormone superfamily. Science 1988;240:889-5.
28. Allenby G, Bocquel MT, Saunders M, Kazmer S, Speck J, Rosenberger M, et al. Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci USA 1993;90(1):30-4.
29. Brand N, Petkovitch M, Krust A, Chambon P, de Thé H, Marchio A, et al. Identification of a second human retinoic acid receptor. Nature 1988;332:850-3.
30. Crettaz M, Baron A, Siegenthaler G, Hunziker W. Ligand specificities of recombinant retinoic acid receptors RAR-α and RAR-β. Biochem J 1990;272:391-7.
31. Levin AA, Struzenbecker LJ, Kazmer S, Bosakowski T, Huselton C, Allenby G, et al. 9-cis-retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature 1992; 355:359-61.
32. Glass CK. Differential recognition of target genes by nuclear receptor monomers, dimers and heterodimers. Endocr Rev 1994;15(3):391-407.
33. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-54.
34. Leid M, Kastner P, Lyons R, Nakshatri H, Saunders M, Zacharewski T, et al. Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 1992;68:377-95.
35. Janknecht R, Hunter T. A growing coactivator network. Nature 1996;383:22-3.
36. Collins S, Robertson K, Mueller L. Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol Cell Biol 1990;10:2154-63.
37. Borrow J, Goddard A, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990;249:1577-80.
38. de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990;347:558-61.
39. Miller WH Jr., Jakubowski A, Tong WP, Miller VA, Rigas JR, Benedetti F, et al. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 1995;85: 3021-7.
40. Miller WH Jr., Warrell RP Jr., Frankel SR, Jakubowski A, Gabrilove JL, Muindi J, et al. Novel retinoic acid receptor transcripts in acute promyelocytic leukemia responsive to all-trans retinoic acid. J Natl Cancer Inst 1990;32:1932-3.
41. Roman SD, Clarke CL, Hall RE, Alexander IE, Sunderland RL. Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res 1992;52:2236-42.
42. Van der Burg, van der Leede BM, Kwakkenbos-Isbrucker L, Salverda S, de Laat SW, van der Saag PT. Retinoic acid resistance of estradiol-independent breast cancer cells coincides with diminished retinoic acid receptor function. Mol Cell Endocrinol 1993;91:149-57.
43. Robertson KA, Emami B, Mueller L, Collins SJ. Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells. Mol Cell Biol 1992;12:3743-9.
44. Dyck JA, Maul GG, Miller WH Jr., Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocytic-retinoic acid receptor oncoprotein. Cell 1994;76:333-43.
45. Rubin M, Fenig E, Rosenauer A, Menendez-Botet C, Achkar C, Bentel JM, et al. 9-cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res 1994;54:6549-56.
46. Formelli F, Barua AB, Olson JA. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl β-glucuronide. FASEB J 1996;10:1014-24.
47. Ong DE, Newcomer ME, Chytil F. Cellular retinoid-binding proteins. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids: biology, chemistry and medicine. 2nd edition. New York: Raven Press, 1994:283-317.
48. McBurney MW, Costa S, Pratt C. Retinoids and cancer: a basis for differentiation therapy. Cancer Invest 1993;11(5): 590-8.
49. Ross AC. Cellular metabolism and activation of retinoids: roles of cellular retinoid-binding proteins. FASEB J 1993;7: 317-27.
50. Takase S, Ong D, Chytil F. Transfer of retinoic acid from its complex with cellular retinoic acid-binding protein to the nucleus. Arch Biochem Biophys 1986;247:328-34.
51. Fiorella PD, Napoli JL. Microsomal retinoic acid metabolism: effects of cellular retinoic acid-binding protein (type I) and C18-hydroxylation as an initial step. J Biol Chem 1994; 269(14):10538-44.
52. Boylan JF, Gudas LJ. Overexpression of the cellular retinoic acid binding protein-I (CRABP-I) results in a reduction in differentiation-specific gene expression in F9 teratocarcinoma cells. J Cell Biol 1991;112:965-79.
53. Fiorella PD, Napoli JL. Expression of cellular retinoic acid binding protein (CRABP) in Escherichia coli. Characterization and evidence that holo-CRABP is a substrate in retinoic acid metabolism. J Biol Chem 1991;266:16572-9.
54. Cornic M, Delva L, Guidez F, Balitrand N, Degos L, Chomienne C. Induction of retinoic acid binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res 1992;52:3329-34.
55. Delva L, Cornic M, Balitrand N, Guidez F, Micléa JM, Delmer A, et al. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993;82:2175-81.
56. Avvisati G, Petti MC, Mandelli F. What is the best treatment for acute promyelocytic leukemia? Leuk Lymphoma 1993;11: 29-35.
57. Schindler J, Matthaei K, Sherman M. Isolation and characterization of mouse mutant embryonal carcinoma cells which fail to differentiate in response to retinoic acid. Proc Natl Acad Sci USA 1981;78:1077-80.
58. Wang SY, Gudas L. Selection and characterization of F9 teratocarcinoma stem cell mutants with altered responses to retinoic acid. J Biol Chem 1984;259:5899-906.
59. Takatsuka J, Takahashi N, De Luca LM. Retinoic acid metabolism and inhibition of cell proliferation: an unexpected liaison. Cancer Res 1996;56:675-8.
60. Roberts AB, Nichols M, Newton D, Sporn MB. In vitro metabolism of retinoic acid in hamster intestine and liver. J Biol Chem 1979;245:6296-302.
61. Frolik CA, Roller PP, Roberts AB, Sporn MB. In vitro and in vivo metabolism of all-trans and 13-cis-retinoic acid in hamsters. Identification of 13-cis-4-oxoretinoic acid. J Biol Chem 1980;255:8057-62.
62. Leo MA, Lasker JM, Raucy JL, Kim CI, Black M, Lieber CS. Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. Arch Biochem Biophys 1989; 269(1): 305-12.
63. Orfanos C, Ehlert R, Gollnick H. The retinoids: a review of their clinical pharmacology and therapeutic use. Drugs 1987;34:459-503.
64. Williams J, Napoli J. Metabolism of retinoic acid and retinol during differentiation of F9 embryonal carcinoma cells. Proc Natl Acad Sci USA 1985;82:4658-62.
65. Van Wauwe J, Coene MC, Goossens J, Van Nijen G, Cools W, Lauwers W. Ketoconazole inhibits the in vitro and in vivo metabolism of all-trans retinoic acid. J Pharmacol Exp Ther 1988;245:718-22.
66. Van Wauwe JP, Coene MC, Goossens J, Cools W, Monbaliu J. Effects of cytochrome P450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J Pharmacol Exp Ther 1990;252:365-9.
67. Miller VA, Rigas JR, Muindi JRF, Tong WP, Venkatraman E, Kris MG, et al. Modulation of all-trans retinoic acid pharmacokinetics by liarozole. Cancer Chemother Pharmacol 1994;34:522-6.
68. Rigas JR, Francis PA, Muindi JRF, Huselton G, DeGrazia F. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst 1993;85(23):1921-6.
69. Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble A-vitamin. J Exp Med 1925;42:753-78.
70. Fujimaki Y. Formation of carcinoma in albino rats fed on deficient diets. J Cancer Res 1926;10:469-77.
71. Strickland S, Mahdavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 1978;15: 393-403.
72. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980;77:2936-40.
73. Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst 1982;68:589-93.
74. Breitman TR, Keene BR, Hemmi H. Retinoic acid-induced differentiation of fresh human leukemia cells and the human myelomonocytic leukemia cell lines, HL-60, U-937 and THP-1. Cancer Surv 1983;2:263-91.
75. Chomienne C, Balitrand N, Cost H, Degos L, Abita JP. Structure-activity relationships of aromatic retinoids on the differentiation of the human histiocytic lymphoma cell line U-937. Leuk Res 1986;10:1301-5.
76. Sherman MI. Retinoids and cell differentiation. Boca Raton: CRC Press, 1986.
77. Leoncini L, Pacenti L, Rusciano D, Burroni D, Garbisa S, Cintorino M, et al. Correlation between differentiation and lung colonization by retinoic acid-treated F9 cells as revealed by the expression pattern of extracellular matrix and cell surface antigens. Am J Pathol 1988;130:505-14.
78. Amos B, Lotan R. Retinoid-sensitive cells and cell lines. Methods Enzymol 1990;190:217-25.
79. Fraker LD, Halter SA, Forbes JT. Growth inhibition by retinol of a human breast carcinoma cell line in vitro and in athymic mice. Cancer Res 1984;44:5757-63.
80. Eccles SA, Barnett SC, Alexander P. Inhibition of growth and spontaneous metastasis of syngeneic transplantable tumors by an aromatic retinoic acid analogue. Cancer Immunol Immunother 1985;19:109-14.
81. Halter SA, Fraker LD, Adcock D, Vick S. Effects of retinoids on xenotransplanted human mammary carcinoma cells in athymic mice. Cancer Res 1988;48:3733-6.
82. Nakajima M, Lotan D, Baig MM, Carralero RM, Wood WR, Hendrix MJC, et al. Inhibition by retinoic acid of type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells. Cancer Res 1989;49:1698-706.
83. De Luca LM, Adamo S, Kato S. Retinoids and cell adhesion. Methods Enzymol 1990;190:81-91.
84. Hendrix MCJ, Wood WR, Seftor EA, Lotan R, Nakajima M, Misiorowski RL, et al. Retinoic acid inhibition of human melanoma invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res 1990;50:4121-30.
85. Lotan R. Retinoids as modulators of tumour cell invasion and metastasis. Semin Cancer Biol 1991;2:197-208.
86. Rusciano D, Terrana B. Analysis of F9 embryonal carcinoma lactosaminoglycans in relation to their differential expression during induction of differentiation. Biochim Biophys Acta 1988;964:8-18.
87. Ledinko N, Fazely F. Reversibility of retinoid effect on sialyltransferase activity, sialic acid content and invasive ability of human lung carcinoma cells. Anticancer Res 1989;9:1669-72.
88. Bollag W. The development of retinoids in experimental and clinical oncology and dermatology. J Am Acad Dermatol 1983;9:797-805.
89. Achkar CC, Derguini F, Blumberg B, Langston A, Levin AA, Speck J, et al. 4-Oxoretinol, a new natural ligand and transactivator of the retinoic acid receptors. Proc Natl Acad Sci USA 1996;93:4879-84.
90. Blumberg BJ, Bolado J Jr., Derguini F, Craig AG, Moreno TA, Chakravarti D, et al. Novel retinoic acid receptors in Xenopus embryos. Proc Natl Acad Sci USA 1996;93:4873-8.
91. Degos L, Dombret H, Chomienne C, Daniel MT, Micléa JM, Chastang C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995;85:2643-53.
92. Jetten AM, Klim JS, Sacks PG, Rearick JI, Lotan D, Hong WK, et al. Inhibition of growth and squamous cell differentiation markers in cultured human head and neck squamous carcinoma cells by all-trans-retinoic acid. Int J Cancer 1990;45: 195-202.
93. Bollag W, Peck R, Frey JR. Inhibition of proliferation by retinoids, cytokines and their combination in four human transformed epithelial cell lines. Cancer Lett 1992;62:167-72.
94. Kizaki M, Ikeda Y, Tanosaki R, Nakajima H, Morikawa M, Sakashita A, et al. Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-β and retinoid X receptor-α RNA by HL-60 cells. Blood 1993;82:3592-9.
95. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
96. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger P, Fenaux P, et al. All-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results. Blood 1990;76:1704-9.
97. Warrell RP Jr., Frankel SR, Miller WH Jr., Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385-93.
98. Chen ZX, Xue YQ, Zhang R, Tao RF, Xia ZM, Li C, et al. A clinical and experimental study of all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78:1413-9.
99. Takeshita A, Shibita Y, Shinjo K, Yanagi M, Tobita T, Ohnishi K, et al. Successful treatment of relapse of acute promyelocytic leukemia with a synthetic retinoid, Am80. Ann Intern Med 1996;124:893-6.
100. Frankel SR, Eardley A, Heller G, Berman E, Miller WH Jr., Dmitrovsky E, et al. All-trans retinoic acid for acute promyelocytic leukemia: results of the New York study. Ann Intern Med 1994;120 278-86.
101. Miller WH Jr., Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr. Detection of minimal residual disease in acute promyelocytic leukaemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 1993;82:1689-94.
102. Warrell RP. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies and implications. Blood 1993;82(7):1949-53.
103. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995;85:1083-94.
104. Cheng AL, Su IJ, Chen CC, Tien HF, Lay JD, Chen BR, et al. Use of retinoic acids in the treatment of peripheral T cell lymphoma: a pilot study. J Clin Oncol 1994;12:1185-92.
105. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueano F, Paredes-Casillas P, Hong WK, et al. 13-cis-retinoic acid plus interferon α-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992;84:241-5.
106. Lippman SM, Parkinson DR, Itri DM, Weber RS, Schantz SP, Ota DM, et al. 13-cis-Retinoic acid and interferon α-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235-41.
107. Lippman SM, Lee JS, Lotan R, Hong KW. Chemoprevention of upper aerodigestive tract cancers. Head Neck 1990;12:5-20.
108. Szarka CE, Grana G, Engstrom PF. Chemoprevention of cancer. Curr Probl Cancer 1994;18(1):6-79.
109. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, et al. Effects of β-tocopherol and β-carotene supplements on cancer incidence in the alpha-tocopherol beta-carotene cancer prevention study. Am J Clin Nutr 1995; 62:(Suppl):1427-30.
110. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334(18):1145-9.
111. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334(18):1150-5.
112. Ocké MC, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, et al. Average intake of anti-oxidant (pro)vitamins and subsequent cancer mortality in the 16 cohorts of the seven countries study. Int J Cancer 1995;61:480-4.
113. Kurie JM, Lippman SM, Hong WK. Potential of retinoids in cancer prevention. Cancer Treat Rev 1994;20:1-10.
114. Alberts DS, Garcia DJ. An overview of clinical cancer chemoprevention studies with emphasis on positive phase III studies. J Nutr 1995;125:S692-7.
115. De Palo G, Formelli F. Risks and benefits of retinoids in the Chemoprevention of cancer. Drug Saf 1995;13(4):245-56.
116. De Vries N, Pastorino U, Van Zandwijk N. Chemoprevention of second primary tumours in head and neck cancer in Europe: EUROSCAN. Eur J Cancer 1994;30B:367-8.
117. Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gander RJ, Newton DL, et al. N-(4-hydroxyphenyl) retinamide: a new retinoid for prevention of breast cancer in the rat. Cancer Res 1979;39:1339-46.
118. Costa A, De Palo G, Decensi A, Sacchini V. Breast cancer chemoprevention with retinoids and tamoxifen [abstract 985]. Eur J Cancer 1995;31A(Suppl 5):S206.
119. Besa EC, Abrahm JL, Bartholomew MJ, Hyzinski M, Nowell PC. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol. Am J Med 1990;89(6):739-47.
120. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The retinoic acid syndrome in acute promyelocytic leukemia. Ann Intern Med 1992;117:292-6.
121. Muindi J, Frankel SR, Miller WH Jr., Jakubowski A, Scheinberg DA, Young CW, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid resistance in patients with acute promyelocytic leukemia. Blood 1992;79:299-303.
122. Wang ZY, Sun GL, Lu JX, Gu LJ, Huang ME, Chen SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China. Nouv Rev Fr Hematol 1990;32:34-6.
123. Peng YM, Dalton WS, Alberts DS, Xu MJ, Lim H, Meyskens FL Jr. Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. Int Cancer 1989;43:22-6.
124. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, et al. The PML/RAR oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 1996;88:2826-32.
125. Rosenauer A, Raelson JV, Eydoux P, DeBlasio A, Miller WH Jr. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood 1996;88:2671-82.
126. Shao WL, Benedetti L, Lamph WW, Nervi C, Miller WH Jr. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR mutation. Blood 1997;89:4282-9.
127. Ding W, Li YP, Nobile LM, Grills G, Carrera I, Tallman MS, et al. Retinoic acid receptor alpha (RARα)-region mutations in the PML/RARα fusion gene of acute promyelocytic leukemia patients after relapse from all-trans retinoic acid (ATRA) therapy [abstract 1846]. Blood 1997;90(Suppl 1):415a.
128. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr., Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature 1998;391:811-4.
129. Van Wauwe J, Van Nyen G, Coene MC, Stoppie P, Cools W, Goossens J, et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exper Ther 1992;261(2):773-9.
130. De Coster R, Wouters W, Van Ginckel R, End D, Krekels M, Coene MC, et al. Experimental studies with liarozole (R 75251), an antitumoral agent which inhibits retinoic acid breakdown. J Steroid Biochem Mol Biol 1992;43:197-201.
131. Krekels MDWG, Zimmerman J, Janssens B, Van Ginckel R, Cools W, Van Hove C, et al. Analysis of the oxidative catabolism of retinoic acid in rat Dunning R3327G prostate tumors. Prostate 1996;29:35-40.
132. Smets G, Van Ginckel R, Daneels G, Moeremans M, Van Wauwe J, Coene MC, et al. Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid. Prostate 1995;27:29-40.
133. Achkar CC, Bentel JM, Boylan JF, Scher HI, Gudas LJ, Miller WH Jr. Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. Drug Metab Dispos Biol Fate Chem 1994;22(3):451-8.
134. Van Wauwe JP, Coene MC, Cools W, Goossens J, Lauwers W, Le Jeune L, et al. Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. Biochem Pharmacol 1994; 47:737-41.
135. Wouters W, van Dun J, Dillen A, Coene MC, Cools W, De Coster R. Effects of liarozole, a new antitumoral compound, on retinoic-acid inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res 1992; 52:2841-6.
136. Van Heusden J, Borgers M, Ramaekers F, Xhonneux B. Wouters W, De Coster R, et al. Liarozole potentiates the all-trans-retinoic acid-induced structural remodelling in human breast carcinoma MCF-7 cells in vitro. Eur J Cancer Biol 1996;71:89-98.
137. Hall AK. Liarozole amplifies retinoid-induced apoptosis in human prostate cancer cells. Anticancer Drugs 1996;7:312-20.
138. Acevedo P, Bertram JS. Liarozole potentiates the cancer chemopreventative activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and β-carotene in 10T1/2 cells. Carcinogenesis 1995;16:2215-22.
139. Westarp ME, Westarp MP, Bollag W, Bruynseels J, Biesalski H, Grossmann N, et al. Effect of six retinoids and retinoic acid catabolic inhibitor liarozole on two glioblastoma cell lines, and in-vivo experience in malignant brain tumor patients. In: Banzet P, Holland JF, Khayat D, Weil M, editors. Cancer treatment - an update. Paris: Springer, 1994:590-8.
140. Elder JT, Kaplan A, Cromie MA, Kang S, Voorhees JJ. Retinoid induction of CRABPII mRNA in human dermal fibroblasts: use as a retinoid bioassay. J Invest Dermatol 1996; 106:517-21.
141. Van Ginckel R, De Coster R, Wouters W, Vanherck W, van der Veer R, Goeminne N, et al. Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats. Prostate 1990;16:313-23.
142. Dijkman A, Van Moorsselaar RJA, Van Ginckel R, Van Stratum P, Wouters W, Debruyne FM, et al. Antitumoral effects of liarozole in androgen-dependent and -independent R3327 Dunning prostate adenocarcinomas. J Urol 1994;151: 217-22.
143. Stearns ME, Wang M, Fudge K. Liarozole and 13-cis retinoic acid anti-prostatic tumour activity. Cancer Res 1993;53: 3073-7.
144. Rao KVN, McCormick DL, Bosland MC, Steele VE, Lubet RA, Kelloff GJ. Chemoprotective evaluation of liarozole fumarate, difluoromethylornithine and oltipraz in the rat prostate [abstract 1864]. Proc AACR 1996;37:273.
145. Denis, L. Liarozole-fumarate (LIA), a novel antitumoral drug: clinical update. Presented at Symposium on Recent Advances in Diagnosis and Treatment of Prostate Cancer, Quebec City, Quebec, Canada, September 21-23, 1995:45.
146. Debruyne JM, Murray R, Fradet Y, Johanssen JE, Tyrell C, Boccardo F, et al. Liarozole, a novel treatment approach for advanced prostate cancer, results of a large randomized trial versus cyproterone acetate. Urology. In press.